GlassScriptPhysician profile
Megan D Johnson
NPI 1457644254
$3,867.03
in general payments reported to CMS, 2019-2025
31 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $171 · 2021: $509 · 2022: $507 · 2023: $601 · 2024: $1,113 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $590.60 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $271.08 | 2021-2025 | |
| Bone Support INC. | $251.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.28 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $194.55 | 2020-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $185.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $155.13 | 2019-2022 | |
| Exact Sciences Corporation | $144.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $98.67 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.59 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $71.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $67.40 | 2019-2024 | Trelegy Ellipta |
| Medtronic, INC. | $67.31 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $66.59 | 2022-2024 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $57.15 | 2020-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $54.30 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $53.92 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $52.28 | 2020-2021 | |
| Amgen INC. | $51.87 | 2019-2020 | |
| Neurelis, INC. | $40.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.13 | 2023-2024 | Jardiance, Tradjenta |
| Alkermes, INC. | $25.36 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.26 | 2025 | Voquezna |
| Evoke Pharma, INC. | $22.47 | 2021 | |
| Axsome Therapeutics, INC. | $18.97 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2025 | Eliquis |
| Corium, LLC | $15.78 | 2023 | Adlarity |
| Biodelivery Sciences International, INC. | $14.86 | 2021 | |
| Advanced Respiratory, INC | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.